← Leaderboards
Stephanie M Downs-Canner
Sloan-Kettering Inst Can Research
$986,679
Attributed
$986,679
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $264.2K · FY2022–25$500K$375K$250K$125K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$986,679 · 1
By mechanism
K08$986,679 · 1
Top collaborators
No co-investigators on record.
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Tobias M Hohl$16,351,909
- Robert Andrew Cramer$16,202,316
- Katharine C Hsu$29,362,365
- Richard John Bennett$14,709,057
- Xiang Zhang$12,735,442
Others in their field
Other Rising Stars on “Cancer Etiology”
- Benjamin Rybicki · Henry Ford Health System$7,553,399
- Joseph P. Uberti · Wayne State University$5,297,337
- Heather Fiegleson · Kaiser Foundation Research Institute$4,979,276
- Joanne Ryan · Hennepin Healthcare Research Institute$4,000,485
- Yicheng Wang · Immunova Therapeutics, Llc$4,000,000
- Matthew Adam Triplette · Fred Hutchinson Cancer Center$2,916,487
Research focus
Cancer EtiologyCancer TherapyAntibody AffinityAffinityActive LearningAntigen PresentationAntigensAntigen TargetingAntibody FormationAntitumor ResponseAntibodiesAntibody ResponseB-Cell ActivationB-Cell Antigen ReceptorBioinformaticsBiological MarkersBiologyB-LymphocytesB-Lymphocyte SubsetsAnti-Tumor Immune ResponseBreast Cancer Cell LineBreast Cancer ModelAwardCancer Type
Grant awards (4)
The role of B-cells in the anti-tumor immune response in triple negative breast cancer$194,124
K08 · FY2025 · CA · contact PI
The role of B-cells in the anti-tumor immune response in triple negative breast cancer$264,185
K08 · FY2024 · CA · contact PI
The role of B-cells in the anti-tumor immune response in triple negative breast cancer$264,185
K08 · FY2023 · CA · contact PI
The role of B-cells in the anti-tumor immune response in triple negative breast cancer$264,185
K08 · FY2022 · CA · contact PI